Latest news

Important Information: ratio-Ectosone (Teva-Ectosone) Type I Recall to Consumer Level

Teva Canada welcomes Fabien Paquette as new General Manager

Important Information - Voluntary Nationwide Recall ratio-Ectosone (TEVA-ECTOSONE) 0.05% Mild lotion 60mL (DIN 00653209)

Important Information on Nicotine Patches

Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry

Government Tour of Teva Canada’s Stouffville Manufacturing Facility Showcases Pharmaceutical Capabilities and Underscores Economic Value to Canada

Important Safety Information on Codeine Antitussive Products

Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY® (fremanezumab), for the preventive treatment of migraine in adults

New public drug plan reimbursement for AJOVY®

Important Information – Voluntary Nationwide Recall - Novo-Gesic Forte® 500 mg (Acetaminophen) Tablets

Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma

Important safety information on prescription cough and cold products containing opioids and the risk of opioid ase disorder in children and adolescents

Teva Canada announces product availability of AJOVY™